Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05012982 · ClinicalTrials.gov registry record · NA

Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction

A NA study of Anterior Cruciate Ligament Reconstruction, sponsored by Yale University.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT05012982 is a NA study of Anterior Cruciate Ligament Reconstruction that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 292-participant average among 11 other Anterior Cruciate Ligament Reconstruction trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05012982, a NA study of Anterior Cruciate Ligament Reconstruction, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.

Interventions

  • DEVICE AirBand
  • DEVICE uninflated AirBand

Study Locations (2)

Connecticut

  • Yale New Haven Hospital - Milford
  • Gaylord Outpatient Physical Therapy North Haven Clinic - North Haven

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-02-16
Est. Completion 2026-05
Phase NA

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT05012982

The ClinicalTrials.gov registry entry for NCT05012982 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 292-participant average among 11 other Anterior Cruciate Ligament Reconstruction trials with a reported enrollment target (93% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Anterior Cruciate Ligament Reconstruction appearing as the primary indexed condition, and to 2 interventions - of which AirBand is the first listed.

NCT05012982 reports 2 study locations spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT05012982 about?

NCT05012982 is a clinical study titled "Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction". This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.

What is the current status of trial NCT05012982?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2023-02-16. Estimated completion is 2026-05.

What conditions does trial NCT05012982 study?

This clinical trial studies the following conditions: Anterior Cruciate Ligament Reconstruction.

What interventions are being tested in trial NCT05012982?

The interventions under investigation include: AirBand (DEVICE), uninflated AirBand (DEVICE).

Who is sponsoring clinical trial NCT05012982?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05012982 being conducted?

This trial has 2 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anterior Cruciate Ligament Reconstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.